A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC early clinical studies group (ECSG)
Date
1996Author

Hanauske, A. R.
Gamucci, T.
Smyth, J. F.
Lehnert, M.
Velde, A. Te
Lan, J.
Verweij, J.
Source
Annals of OncologyVolume
7Issue
5Pages
529-531Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
In a multicentre randomized trial of the EORTC-ECSG, we have treated 38 chemotherapy naive patients with advanced non-small-cell lung cancer (NSCLC) with EO9, a novel bioreductive alkylating indoloquinone. The drug was given at two different dose schedules by a single bolus i.v. injection: arm A 12 mg/m2 weekly and arm B 22 mg/m2 every three weeks. All together 185 courses were administered (145 in arm A and 40 in arm B). The major toxicity was reversible proteinuria more frequently occurring in the three-weekly schedule (arm A 34.5% vs. arm B 62.5%). Creatinine elevation, fluid retention and pericardial or pleural effusion were also recorded in a limited number of patients. Other common toxicities more frequent in the three-weekly administration were asthenia (21% vs. 35% of cycles), nausea (15% vs. 27.5% of cycles) and Vomiting (5% vs. 17.5% of cycles). Toxicities were mainly of grade I and II. No responses have been observed. Five patients (26%) on arm A and eight (53%) on arm B experienced stable disease. These doses and schedules of EO9 do not yield activity in NSCLC.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: A study of the EORTC early clinical studies group (ECSG)
Pavlidis, Nicholas; Aamdal, S.; Awada, Ahmad; Calvert, H.; Fumoleau, P.; Sorio, R.; Punt, C.; Verweij, J.; Oosterom, A. T. Van; Morant, R.; Wanders, J.; Hanauske, A. R. (2000)Purpose: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. Patients and methods: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ...
-
Article
Organization Studies: The Fourth Organization Studies Summer Workshop: “Embracing Complexity: Advancing Ecological Understanding in Organization Studies” 5—7 June 2008, Pissouri, Cyprus
Dooley, K. J.; Sandelands, L.; Tsoukas, Haridimos (2007)
-
Article
Multifocal extranodal non-Hodgkin lymphoma: A clinicopathologic study of 37 cases in Greece, a Hellenic Cooperative Oncology Group Study
Economopoulos, T.; Papageorgiou, S.; Rontogianni, D.; Kaloutsi, V.; Fountzilas, George; Tsatalas, C.; Pavlidis, Nicholas; Pectasides, Dimitrios; Papageorgiou, E.; Dimopoulos, M. A. (2005)The purpose of this retrospective study was to illustrate the clinicopathological features of patients presenting with multifocal extranodal non-Hodgkin lymphoma (NHL). Among 810 patients with NHL, 37 cases (4.2%) were ...